MBRX · Moleculin Biotech, Inc.

Summary

Moleculin Biotech announced preclinical data for Annamycin in pancreatic cancer, showing significant tumor growth inhibition and survival benefit.

Key takeaways

• Liposomal Annamycin (L-ANN) showed significant tumor growth inhibition in PDAC models (p<0.001).
• Median survival extended by >60% in metastatic model (29 vs 18 days, p=0.0003).
• Annamycin demonstrated higher tumor accumulation than doxorubicin (p<0.0001).
• L-ANN induced CD8+ and CD4+ T cell infiltration, suggesting potential for combination therapies.
• Annamycin continued to show absence of cardiotoxicity, a key advantage over conventional anthracyclines.